OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesday the final data from a phase 2a trial showed its investigational vaccine VXM01 in combination with avelumab "could offer meaningful clinical benefit" in patients with recurrent glioblastoma, a type of aggressive brain cancer.
Intraday trading volume catapulted to over 75.2 million shares from a daily average of about 1.2 million.
VivoPower International (VVPR) said Wednesday it is in advanced talks with Abu Dhabi-based Energi Holdings on an unsolicited all-cash takeover bid for $120 million. Negotiations between VivoPower's board and Energi are expected to be completed by April 2.
Shares soared 75% as intraday trading volume surged to more than 132 million from a daily average of about 2.7 million.
SurgePays (SURG) said overnight that it expects revenue to exceed $200 million over the next 12 months, compared with sales of $60.9 million reported in 2024.
Shares jumped 61% as intraday trading volume soared to over 63.9 million from a daily average of roughly 295,000.
Price: 3.46, Change: +1.86, Percent Change: +116.44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.